- Home
- CLLS vs MSD Comparison
CLLS vs MSD Comparison
Compare CLLS & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- MSD
- Stock Information
- Founded
- CLLS 1999
- MSD 1993
- Country
- CLLS France
- MSD United States
- Employees
- CLLS N/A
- MSD N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- MSD Trusts Except Educational Religious and Charitable
- Sector
- CLLS Health Care
- MSD Finance
- Exchange
- CLLS Nasdaq
- MSD Nasdaq
- Market Cap
- CLLS 148.1M
- MSD 162.9M
- IPO Year
- CLLS 2007
- MSD N/A
- Fundamental
- Price
- CLLS $1.32
- MSD $8.09
- Analyst Decision
- CLLS Buy
- MSD
- Analyst Count
- CLLS 3
- MSD 0
- Target Price
- CLLS $7.00
- MSD N/A
- AVG Volume (30 Days)
- CLLS 839.3K
- MSD 70.2K
- Earning Date
- CLLS 03-13-2025
- MSD 01-01-0001
- Dividend Yield
- CLLS N/A
- MSD 11.26%
- EPS Growth
- CLLS N/A
- MSD N/A
- EPS
- CLLS N/A
- MSD N/A
- Revenue
- CLLS $49,217,000.00
- MSD N/A
- Revenue This Year
- CLLS $1.26
- MSD N/A
- Revenue Next Year
- CLLS N/A
- MSD N/A
- P/E Ratio
- CLLS N/A
- MSD N/A
- Revenue Growth
- CLLS 435.38
- MSD N/A
- 52 Week Low
- CLLS $1.14
- MSD $6.11
- 52 Week High
- CLLS $3.38
- MSD $7.46
- Technical
- Relative Strength Index (RSI)
- CLLS 49.18
- MSD 45.08
- Support Level
- CLLS $1.16
- MSD $7.84
- Resistance Level
- CLLS $1.35
- MSD $8.32
- Average True Range (ATR)
- CLLS 0.07
- MSD 0.11
- MACD
- CLLS 0.01
- MSD -0.02
- Stochastic Oscillator
- CLLS 69.23
- MSD 51.04
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.